Literature DB >> 10719618

Effects of chondroitin sulfate-C on articular cartilage destruction in murine collagen-induced arthritis.

T Omata1, Y Itokazu, N Inoue, Y Segawa.   

Abstract

The effects of chondroitin sulfate-C (CAS 25322-46-7, Chondroitin ZS Tab) on type II collagen (CII)-induced arthritis (CIA) in mice were evaluated. DBA/1J mice were immunized with bovine CII emulsified in Freund's complete adjuvant, followed by a booster injection 21 days later. Chondroitin sulfate-C at doses of 100, 300 and 1000 mg/kg was administered orally once daily beginning 14 days before initial immunization. An arthritis index and hind paw edema were examined from day 0 to day 49, when the mice were killed by ether anesthesia for histopathological examination. The delayed-type hypersensitivity (DTH) reaction, serum anti-CII antibody titer, and histopathologic characteristics of both synovitis and destruction of articular cartilage were analyzed. Both the arthritis index and the serum anti-CII antibody titer were reduced by treatment with chondroitin sulfate-C in a dose-dependent manner. Chondroitin sulfate-C (1000 mg/kg) significantly inhibited hind paw edema, synovitis and destruction of the articular cartilage, but not DTH reaction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10719618     DOI: 10.1055/s-0031-1300180

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

Review 1.  Chondroitin and glucosamine in the management of osteoarthritis: an update.

Authors:  Yves Henrotin; Cécile Lambert
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

Review 2.  Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule.

Authors:  Nicola Volpi
Journal:  Inflammopharmacology       Date:  2011-11-01       Impact factor: 4.473

3.  Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations.

Authors:  Yves Henrotin; Mariane Mathy; Christelle Sanchez; Cecile Lambert
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-12       Impact factor: 5.346

Review 4.  Targeting the synovial angiogenesis as a novel treatment approach to osteoarthritis.

Authors:  Yves Henrotin; Laurence Pesesse; Cecile Lambert
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

Review 5.  Drug Screening Implicates Chondroitin Sulfate as a Potential Longevity Pill.

Authors:  Collin Y Ewald
Journal:  Front Aging       Date:  2021-09-08

6.  Chondroitin sulfate prevents peritoneal fibrosis in mice by suppressing NF-κB activation.

Authors:  Shinichi Abe; Yoko Obata; Satoru Oka; Takehiko Koji; Tomoya Nishino; Koichi Izumikawa
Journal:  Med Mol Morphol       Date:  2016-02-15       Impact factor: 2.309

7.  Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI.

Authors:  Lukas Martin Wildi; Jean-Pierre Raynauld; Johanne Martel-Pelletier; André Beaulieu; Louis Bessette; Frédéric Morin; François Abram; Marc Dorais; Jean-Pierre Pelletier
Journal:  Ann Rheum Dis       Date:  2011-03-01       Impact factor: 19.103

8.  Comparison of various SYSADOA for the osteoarthritis treatment: an experimental study in rabbits.

Authors:  María Permuy; David Guede; Mónica López-Peña; Fernando Muñoz; José-Ramón Caeiro; Antonio González-Cantalapiedra
Journal:  BMC Musculoskelet Disord       Date:  2015-05-20       Impact factor: 2.362

9.  Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats.

Authors:  Giuseppe M Campo; Angela Avenoso; Salvatore Campo; Alida M Ferlazzo; Domenica Altavilla; Alberto Calatroni
Journal:  Arthritis Res Ther       Date:  2003-03-06       Impact factor: 5.156

Review 10.  Immunomodulatory and anti-inflammatory effects of chondroitin sulphate.

Authors:  Patrick du Souich; Antonio G García; Josep Vergés; Eulàlia Montell
Journal:  J Cell Mol Med       Date:  2009-06-11       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.